- The FDA approves Orexigen Therapeutics' (NASDAQ:OREX) Contrave (naltrexone hydrochloride and bupropion hydrochloride extended-release tablets) as a treatment option for chronic weight management in addition to a reduced-calorie diet and physical activity.
- Contrave is indicated for use in adults with a body mass index (BMI) of 30 or greater (obese) or adults with a BMI of 27 or greater who have at least one weight-related co-morbidity (e.g. hypertension, type 2 diabetes, high cholesterol).
- Takeda Pharmaceuticals will be the distributor of the product for Orexigen.
- Orexigen will conduct a conference call this morning at 8:30 am EDT to discuss Contrave's approval and launch. Interested persons can participate via 800-708-4540.
- Related tickers: (ARNA) (VVUS)